Alnylam Reports P-II Study (KARDIA-1) Results of Zilebesiran for Hypertension in Patients at High Cardiovascular Risk
- The P-II study evaluates zilebesiran (RNAi therapeutic targeting liver-expressed AGT) as monotx. vs PBO in 394 adults. The trial met its 1EPs & showed a dose-dependent, clinical reduction in 24hr. mean systolic blood pressure (SBP) at 3mos. with PBO-subtracted reduction ≥15mmHg with 300 & 600mg doses
- The study also met 2EPs incl. significant change in 24hr. mean SBP at 6mos., change in office SBP at 3 & 6mos. Zilebesiran was associated with dose-dependent, potent, and durable knockdown of serum AGT levels through 6mos. & demonstrated an encouraging safety & tolerability profile, SAEs (3.6% vs 6.7%)
- The P-II (KARDIA-2) study results of zilebesiran in combination with one of three standard classes of anti-hypertensive medications are expected in early 2024
Ref: Businesswire | Image: Alnylam
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.